In preclinical studies, HDAC inhibitors have shown initial promise in suppressing hypertrophic cardiomyopathy, a common source of morbidity and mortality in patients with RASopathy (Ferguson et al., 2013). This evidence concerns the gene HDAC9 and RASopathy.